RxDoctor Payments Data

Liwen Huang, MD

Internal Medicine · Elmhurst, NYNPI 1992035257

Payments from drug & device makers

$1,775in general payments, 2019–2025

Across 69 payments — averaging $25.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$737
  • AbbVie$403
  • Amgen$223
  • Amarin Pharma, Inc.$155
  • AstraZeneca$83
  • Merck$43
  • plus $132 from 5 others

What the payments were for

  • Food & beverage$1,71697%
  • Education$593%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,775 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$49,865
Medicare patients
47
Services billed
713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol178$163,799
VascepaIcosapent Ethyl346$155,926
JanuviaSitagliptin Phosphate101$78,409
JardianceEmpagliflozin102$70,711
Diclofenac Epolamine93$47,395
VemlidyTenofovir Alafenamide30$42,537
EliquisApixaban41$37,396
TrulicityDulaglutide18$36,874
ProliaDenosumab15$25,707
OzempicSemaglutide25$25,530
XareltoRivaroxaban24$23,201
KerendiaFinerenone17$16,092
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,900
RybelsusSemaglutide14$13,425
AbrysvoRsv Vacc, Pref A And Pref B/Pf41$11,952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$83$163,799178 claims
MerckJanuvia$43$78,409101 claims
GileadVemlidy$737$42,53730 claims
Novo NordiskOzempic, Rybelsus$41$38,95539 claims
GSKTrelegy Ellipta, Shingrix, Anoro Ellipta, Incruse Ellipta$18$38,431119 claims
Lilly USA, LLCTrulicity$42$36,87418 claims
AmgenProlia$223$25,70715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elmhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →